Literature DB >> 28866612

DNA repair-related functional assays for the classification of BRCA1 and BRCA2 variants: a critical review and needs assessment.

Amanda Ewart Toland1, Paul R Andreassen2,3.   

Abstract

Mutation of BRCA1 and BRCA2 is the most common cause of inherited breast and ovarian cancer. Genetic screens to detect carriers of variants can aid in cancer prevention by identifying individuals with a greater cancer risk and can potentially be used to predict the responsiveness of tumours to therapy. Frequently, classification cannot be performed based on traditional approaches such as segregation analyses, including for many missense variants, which are therefore referred to as variants of uncertain significance (VUS). Functional assays provide an important alternative for classification of BRCA1 and BRCA2 VUS. As reviewed here, both of these tumour suppressors promote the maintenance of genome stability via homologous recombination. Thus, related assays may be particularly relevant to cancer risk. Progress in implementing functional assays to assess missense variants of BRCA1 and BRCA2 is considered here, along with current limitations and the path to more impactful assay systems. While functional assays have been developed to independently evaluate BRCA1 and BRCA2 VUS, high-throughput assays with sufficient sensitivity to characterise the large number of identified variants are lacking. Additionally, because of relatively low conservation of certain domains of BRCA1, and of BRCA2, between humans and rodents, heterologous expression in rodent cells may have limited reliability or capacity to assess variants present throughout either protein. Moving forward, it will be important to perform assays in human cell lines with relevance to particular tumour types, and to strengthen risk predictions based on multifactorial statistical analyses that also include available data on cosegregation and tumour pathology. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  BRCA1; BRCA2; functional classification; hereditary breast and ovarian cancer; variants of uncertain significance

Mesh:

Substances:

Year:  2017        PMID: 28866612     DOI: 10.1136/jmedgenet-2017-104707

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  17 in total

1.  Impact of amino acid substitutions at secondary structures in the BRCT domains of the tumor suppressor BRCA1: Implications for clinical annotation.

Authors:  Vanessa C Fernandes; Volha A Golubeva; Giuliano Di Pietro; Cara Shields; Kwabena Amankwah; Thales C Nepomuceno; Giuliana de Gregoriis; Renata B V Abreu; Carly Harro; Thiago T Gomes; Ricceli F Silva; Guilherme Suarez-Kurtz; Fergus J Couch; Edwin S Iversen; Alvaro N A Monteiro; Marcelo A Carvalho
Journal:  J Biol Chem       Date:  2019-02-14       Impact factor: 5.157

Review 2.  Navigating the nuances of clinical sequence variant interpretation in Mendelian disease.

Authors:  Natasha T Strande; Sarah E Brnich; Tamara S Roman; Jonathan S Berg
Journal:  Genet Med       Date:  2018-07-10       Impact factor: 8.822

3.  The p.Ser64Leu and p.Pro104Leu missense variants of PALB2 identified in familial pancreatic cancer patients compromise the DNA damage response.

Authors:  Yue Zhang; Jung-Young Park; Fan Zhang; Sara H Olson; Irene Orlow; Yirong Li; Robert C Kurtz; Marc Ladanyi; Jie Chen; Amanda E Toland; Liying Zhang; Paul R Andreassen
Journal:  Hum Mutat       Date:  2020-12-16       Impact factor: 4.878

4.  High-throughput functional evaluation of BRCA2 variants of unknown significance.

Authors:  Masachika Ikegami; Shinji Kohsaka; Toshihide Ueno; Yukihide Momozawa; Satoshi Inoue; Kenji Tamura; Akihiko Shimomura; Noriko Hosoya; Hiroshi Kobayashi; Sakae Tanaka; Hiroyuki Mano
Journal:  Nat Commun       Date:  2020-05-22       Impact factor: 14.919

5.  Incidence of adrenal gland tumor as a second primary malignancy: SEER-based study.

Authors:  Wafaa M Rashed; Anas M Saad; Muneer J Al-Husseini; Ahmed Mahmoud Galal; Assem Mohamed Ismael; Ahmed M Al-Tayep; Ayman El Shafie; Mahmoud Ahmed Ali; Ahmed Samir Alfaar
Journal:  Endocr Connect       Date:  2018-08-23       Impact factor: 3.335

6.  Identifying a BRCA2 c.5722_5723del mutation in a Han-Chinese family with breast cancer.

Authors:  Yi Guo; Peng Wang; Xiaorong Li; Shaihong Zhu; Hongbo Xu; Shizhou Li; Hao Deng; Lamei Yuan
Journal:  Biosci Rep       Date:  2019-04-30       Impact factor: 3.840

7.  Reviewing the characteristics of BRCA and PALB2-related cancers in the precision medicine era.

Authors:  Gabriel S Macedo; Barbara Alemar; Patricia Ashton-Prolla
Journal:  Genet Mol Biol       Date:  2019-04-29       Impact factor: 1.771

8.  A Functional Analysis of the Unclassified Pro2767Ser BRCA2 Variant Reveals Its Potential Pathogenicity that Acts by Hampering DNA Binding and Homology-Mediated DNA Repair.

Authors:  Maria Valeria Esposito; Giuseppina Minopoli; Luciana Esposito; Valeria D'Argenio; Federica Di Maggio; Emanuele Sasso; Massimiliano D'Aiuto; Nicola Zambrano; Francesco Salvatore
Journal:  Cancers (Basel)       Date:  2019-09-28       Impact factor: 6.639

9.  Impact of proactive high-throughput functional assay data on BRCA1 variant interpretation in 3684 patients with breast or ovarian cancer.

Authors:  Jong Won Lee; Woochang Lee; Hyun-Ki Kim; Eun Jin Lee; Young-Jae Lee; Jisun Kim; Yongsub Kim; Kyunggon Kim; Shin-Wha Lee; Suhwan Chang; Young Joo Lee; Sail Chun; Byung Ho Son; Kyung Hae Jung; Yong-Man Kim; Won-Ki Min; Sei-Hyun Ahn
Journal:  J Hum Genet       Date:  2020-01-06       Impact factor: 3.172

10.  A new bioinformatics tool to help assess the significance of BRCA1 variants.

Authors:  Isabelle Cusin; Daniel Teixeira; Monique Zahn-Zabal; Valentine Rech de Laval; Anne Gleizes; Valeria Viassolo; Pierre O Chappuis; Pierre Hutter; Amos Bairoch; Pascale Gaudet
Journal:  Hum Genomics       Date:  2018-07-11       Impact factor: 4.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.